Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer

Author： Rosanò Laura   Cianfrocca Roberta   Spinella Francesca   Di Castro Valeriana   Natali Pier G.   Bagnato Anna  

Publisher： NRC Research Press

ISSN： 1205-7541

Source： Canadian Journal of Physiology and Pharmacology, Vol.88, Iss.6, 2010-06, pp. : 676-681

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeted therapy for epithelial ovarian cancer

By Sharma Sameer   Odunsi Kunle  

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 3, 2005-06 ,pp. : 501-513

Informa Healthcare

Access to resources Recommend Favorite

Bevacizumab Combination Therapy: For the First-Line Treatment of Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

By Dhillon Sohita  

Drugs, Vol. 72, Iss. 7, 2012-05 ,pp. : 917-930

Adis International

Access to resources Recommend Favorite

Editorial: Advances in Epithelial Ovarian Cancer Therapy

By  

Current Pharmaceutical Design, Vol. 18, Iss. 25, 2012-07 ,pp. : 3735-3740

Bentham Science Publishers

Access to resources Recommend Favorite

Combination gemcitabine + cisplatin therapy for recurrent ovarian cancer

By  

Inpharma, Vol. 1, Iss. 1376, 2003-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study

By Chen Kai   Chen Wan   Chen Xia   Jia Yi   Peng Gui   Chen Li  

European Journal of Drug Metabolism and Pharmacokinetics, Vol. 39, Iss. 1, 2014-03 ,pp. : 25-31

Springer Publishing Company

Access to resources Recommend Favorite